[ad_1]
The Austrian Federal Health Service (BASG) has received two notifications, possibly related to the vaccination of the same batch of AstraZeneca vaccine. A study is currently underway to investigate two suspected adverse reactions in Austria, thrombosis and pulmonary embolism.
SAM and international experts emphasize that there are no objective reasons to worry or worry. Based on data from clinical trials, thromboembolism is not a typical side effect of AstraZeneca. International analysis initiated of side effect reports also does not show similar cases in the past. In order to ensure public safety and clear up doubts, the goal is to verify any assumptions about the safety of vaccines.
On February 11, 9600 vaccines of this series were delivered to Lithuania, currently unused in 1932. Vaccines of the ABV5300 series were delivered to 17 countries of the European Union. Luxembourg, Estonia, Greece, Austria and Lithuania have currently discontinued the use of this series of AstraZeneca vaccines.
It is important to note that during large-scale vaccination not only in our country, but also around the world, Lithuania constantly monitors and analyzes all information on suspected adverse reactions after the COVID-19 vaccine and takes appropriate measures. .
It is recalled that in mid-January, the vaccination process had already been suspended for a short time due to the use of the BioNTech and Pfizer vaccine, when SAM was informed of a potentially damaged cold chain during transport. The vaccination process was resumed after receiving official approval from the Pfizer representative office in Lithuania regarding the possible further use of the vaccine.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to indicate DELFI as the source .
[ad_2]
